Michail A. Belyavskyi

Array ( [id] => 17286266 [patent_doc_number] => 11202804 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-21 [patent_title] => Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy [patent_app_type] => utility [patent_app_number] => 17/383272 [patent_app_country] => US [patent_app_date] => 2021-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 138 [patent_figures_cnt] => 196 [patent_no_of_words] => 104260 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 210 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17383272 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17539875 [patent_doc_number] => 11304979 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-19 [patent_title] => Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy [patent_app_type] => utility [patent_app_number] => 17/383280 [patent_app_country] => US [patent_app_date] => 2021-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 138 [patent_figures_cnt] => 196 [patent_no_of_words] => 104322 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 207 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17383280 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17392468 [patent_doc_number] => 11241456 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-08 [patent_title] => Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy [patent_app_type] => utility [patent_app_number] => 17/382831 [patent_app_country] => US [patent_app_date] => 2021-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 138 [patent_figures_cnt] => 196 [patent_no_of_words] => 104133 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 309 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17382831 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17466723 [patent_doc_number] => 11273180 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-15 [patent_title] => Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy [patent_app_type] => utility [patent_app_number] => 17/383276 [patent_app_country] => US [patent_app_date] => 2021-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 138 [patent_figures_cnt] => 196 [patent_no_of_words] => 104241 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 301 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17383276 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18626753 [patent_doc_number] => 20230285559 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-14 [patent_title] => THERAPEUTIC HYDROGEL FOR THE DELIVERY OF CAR-T CELLS [patent_app_type] => utility [patent_app_number] => 18/015709 [patent_app_country] => US [patent_app_date] => 2021-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8692 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18015709 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17213168 [patent_doc_number] => 20210346504 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => Exosomes For Delivery Of Biotherapeutics [patent_app_type] => utility [patent_app_number] => 17/380388 [patent_app_country] => US [patent_app_date] => 2021-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7215 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17380388 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20240996 [patent_doc_number] => 12421304 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-23 [patent_title] => Method for inhibiting bone resorption [patent_app_type] => utility [patent_app_number] => 17/376304 [patent_app_country] => US [patent_app_date] => 2021-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 10175 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17376304 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20240996 [patent_doc_number] => 12421304 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-23 [patent_title] => Method for inhibiting bone resorption [patent_app_type] => utility [patent_app_number] => 17/376304 [patent_app_country] => US [patent_app_date] => 2021-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 10175 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17376304 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18550799 [patent_doc_number] => 20230248799 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-10 [patent_title] => COMBINATION THERAPY OF SUBSTANCE-P FOR MOBILIZATION OF HEMATOPOIETIC STEM CELLS [patent_app_type] => utility [patent_app_number] => 18/014554 [patent_app_country] => US [patent_app_date] => 2021-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4685 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18014554 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18581649 [patent_doc_number] => 20230263902 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 18/010783 [patent_app_country] => US [patent_app_date] => 2021-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56415 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -83 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18010783 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20385482 [patent_doc_number] => 12485192 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-02 [patent_title] => Cellular targeted label delivery system [patent_app_type] => utility [patent_app_number] => 17/361897 [patent_app_country] => US [patent_app_date] => 2021-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 10 [patent_no_of_words] => 14679 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17361897 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17315984 [patent_doc_number] => 20210405032 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => FUNCTIONAL VALIDATION OF DONOR IMMUNE-REGULATORY CELLS [patent_app_type] => utility [patent_app_number] => 17/360886 [patent_app_country] => US [patent_app_date] => 2021-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4578 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17360886 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17421468 [patent_doc_number] => 11254913 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-02-22 [patent_title] => Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy [patent_app_type] => utility [patent_app_number] => 17/353430 [patent_app_country] => US [patent_app_date] => 2021-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 151 [patent_figures_cnt] => 208 [patent_no_of_words] => 135179 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 230 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17353430 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18274638 [patent_doc_number] => 11613569 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-28 [patent_title] => Identifying human B cells expressing anti-allergen antibodies [patent_app_type] => utility [patent_app_number] => 17/351053 [patent_app_country] => US [patent_app_date] => 2021-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 74 [patent_no_of_words] => 64090 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 175 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17351053 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18529940 [patent_doc_number] => 20230235007 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => HUMANIZED ACE2-FC FUSION PROTEIN FOR TREATMENT AND PREVENTION OF SARS-COV-2 INFECTION [patent_app_type] => utility [patent_app_number] => 18/001947 [patent_app_country] => US [patent_app_date] => 2021-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18472 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18001947 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18468888 [patent_doc_number] => 20230203171 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => AQUEOUS PHARMACEUTICAL COMPOSITION OF LEVILIMAB [patent_app_type] => utility [patent_app_number] => 17/998567 [patent_app_country] => US [patent_app_date] => 2021-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21457 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -63 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17998567 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18612384 [patent_doc_number] => 20230279116 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => COMBINATION OF AN ATP-HYDROLYZING ENZYME AND AN IMMUNE CHECKPOINT MODULATOR AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/999455 [patent_app_country] => US [patent_app_date] => 2021-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40297 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17999455 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18612384 [patent_doc_number] => 20230279116 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => COMBINATION OF AN ATP-HYDROLYZING ENZYME AND AN IMMUNE CHECKPOINT MODULATOR AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/999455 [patent_app_country] => US [patent_app_date] => 2021-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40297 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17999455 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17080586 [patent_doc_number] => 20210275592 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-09 [patent_title] => Immune Cells with DNMT3A Gene Modifications and Methods Related Thereto [patent_app_type] => utility [patent_app_number] => 17/330378 [patent_app_country] => US [patent_app_date] => 2021-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10577 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17330378 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18434455 [patent_doc_number] => 20230181749 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/926454 [patent_app_country] => US [patent_app_date] => 2021-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9310 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17926454 [rel_patent_id] =>[rel_patent_doc_number] =>)